Condition: Hepatocellular Carcinoma Non-resectable · Sponsor: Terumo Europe N.V.
The primary objective of the study is to confirm safety and technical success of BioPearl™ microspheres loaded with Doxorubicin in the treatment of unresectable hepatocellular carcinoma (HCC). The secondary objective of the study is to investigate the efficacy of BioPearl™ microspheres loaded with Doxorubicin in the treatment of subjects with unresectable HCC.
This description comes directly from the study's public registry record.
Tamara Sals · +32 483 53 41 06 · tamara.sals@terumo-europe.com
Florence Chow · +32 163 81 645 · florence.chow@terumo-europe.com
Always discuss trial participation with your own doctor first.
| CUB Hôpital Erasme | Brussels, Belgium | Recruiting |
| UZ Leuven | Leuven, Belgium | Recruiting |
| Beaujon Hospital | Clichy, France | Recruiting |
| CHU Grenobles (Hôpital Michallon) | La Tronche, France | Not Yet Recruiting |
| Paul-Brousse Hospital | Villejuif, France | Recruiting |
| SLK-Kliniken Heilbronn | Heilbronn, Germany | Recruiting |
| University Hospital Tübingen | Tübingen, Germany | Recruiting |
| Fondazione IRCCS Instituto Tumori | Milan, Italy | Recruiting |
| Fondazione Policlinico Universitario A. Gemelli | Rome, Italy | Recruiting |
| Città della Salute e della Scienza di Torino | Turin, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05911633